Table 2.
Therapeutic efficacy of chemotherapy plus bevacizumab (experimental group) versus chemotherapy alone (control group)
| First author | PFS (median months) | OS (median months) | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| B | C | P | HR (95% CI) | B | C | P | HR (95% CI) | |
| Kabbinavar BF | 7.4 | 5.2 | 0.013 | 0.54 (0.31-0.94) | 21.5 | 13.8 | < 0.001 | 0.86 (0.44-1.68) |
| Hurwitz H | 10.6 | 6.2 | < 0.001 | 0.54 (0.45-0.65) | 20.3 | 15.6 | < 0.001 | 0.66 (0.54-0.81) |
| Kabbinavar FF | 9.2 | 5.5 | 0.0002 | 0.50 (0.34-0.73) | 16.6 | 12.9 | 0.016 | 0.79 (0.56-1.10) |
| Saltz LB | 10.4 | 7.9 | <0.0001 | 0.83 (0.74-0.93) | 21.3 | 19.9 | 0.0769 | 0.89 (0.76-1.03) |
| Stathopoulos GP | - | - | - | - | 22 | 25 | 0.1391 | 1.05 (0.81-1.36) |
| Tebbutt NC | 8.5 | 5.7 | < 0.001 | 0.63 (0.50-0.80) | 18.9 | 18.9 | 0.314 | 0.88 (0.68-1.14) |
| Guan ZZ | 8.3 | 4.2 | < 0.001 | 0.44 (0.31-0.63) | 18.7 | 13.4 | 0.014 | 0.62 (0.41-0.95) |
| Zhang HM | 10.1 | 5.1 | 0.002 | 0.65 (0.60-0.71) | 18 | 11 | 0.016 | 0.83 (0.41-1.69) |
| Cunningham D | 9.1 | 5.1 | < 0.0001 | 0.53 (0.41-0.69) | 20.7 | 16.8 | 0.18 | 0.79 (0.57-1.09) |
PFS: Progression-free survival; OS, overall Survival; HR: Hazard ratio; 95% CI, 95% confidence interval; B: Bevacizumab-based group/Experimental group; C: Control group; P: P-value.